Critic at Large

» techniques, science policy and regulation

Most Recent

image: Opinion: Improving FDA Evaluations Without Jeopardizing Safety and Efficacy

Opinion: Improving FDA Evaluations Without Jeopardizing Safety and Efficacy

By | February 1, 2017

What can be done to lower development costs and drug prices?

4 Comments

image: Getting Animal Research Right

Getting Animal Research Right

By | March 1, 2016

Regulatory and compliance expectations for animal-based research are demanding, while public and political scrutiny of animal research is rising.

2 Comments

image: The Great Divide

The Great Divide

By | December 1, 2013

A two-way bridge between science and policy is desperately needed.

2 Comments

image: Proceed with Caution

Proceed with Caution

By | October 1, 2013

While genomic data sharing is essential for research, scientists must work to keep sensitive, potentially damaging information under wraps.

1 Comment

image: Border Buffers

Border Buffers

By | April 1, 2013

Protected areas help to conserve imperiled tropical forests, but many are struggling to sustain their resident species.

0 Comments

image: DIYbio: Low Risk, High Potential

DIYbio: Low Risk, High Potential

By | March 1, 2013

Citizen scientists can inspire innovation and advance science education—and they are proving adept at self-policing.

5 Comments

image: Regulating Amateurs

Regulating Amateurs

By | March 1, 2013

How should the government ensure the safety and responsibility of do-it-yourself biologists?

2 Comments

image: Medicines for the World

Medicines for the World

By | October 1, 2012

A global R&D treaty could boost innovation and improve the health of the world’s poor—and rich.

0 Comments

image: Science and Democracy

Science and Democracy

By | October 1, 2012

Researchers and conscientious citizens must unite against the partisan rancor in American politics and restore the role of scientific information in policymaking.

1 Comment

image: Regulations for Biosimilars

Regulations for Biosimilars

By | June 1, 2012

As biologic drug patents begin to expire, generic versions will hit the market—but how will they be regulated?

2 Comments

Popular Now

  1. Opinion: Why I Published in a Predatory Journal
    News & Opinion Opinion: Why I Published in a Predatory Journal

    My “colleagues” and I at the fictitious Arthur Vandelay Urological Research Institute were surprised to find our bogus “uromycitisis” case report swiftly accepted, with only minor revisions requested.

  2. Consilience, Episode 3: Cancer, Obscured
  3. Genetic Analysis Reveals the Evolutionary History of Dogs
  4. March for Science: Dispatches from Washington, DC
AAAS